UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie

13/01/2016 - 2 minutes

This year has started with a rush of deals for many Biotechs. F-Star another such company, now signing up for an Immuno-Oncology deal with AbbVie using Bispecific Antibodies.

abbvie_f-star_jane_dancer_biotechFinancial terms were not disclosed but in regards to the hype of the Immuno-Oncology field, it could be pretty high. F-Star is a Cambridge company based at the Babraham Institute campus, the bioincubator we visited on our Labiotech tour of the UK (and listed as our top Bioincubator in Europe).

So what are they doing? F-Star are developing and ‘discovering’ bispecific monoclonal antibodies to further enhance the potency, safety profile and cost efficiency of immuno-oncology treatments.

Their modular Antibody technology platform introduces an antigen binding site into the constant region of an antibody to create a so-called Fcab (an Fc-domain with antigen binding activity).

In a combinatorial plug & play process, an Fcab can then be used to make many different bispecific antibodies (mAb2) using variable regions binding to second targets –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member